Perspective

Endobronchial treatment of peripheral tumors: ongoing development and perspectives

Thibault Vieira, Jean-Baptiste Stern, Philippe Girard, Raffaelle Caliandro

Introduction

As the capabilities of computed tomography (CT) scanners have progressed, higher levels of spatial resolution reveal tinier lung tumors. This situation has become a routine practice for the thorax specialists. Modern diagnostic tools, such as electromagnetic navigation (ENB) or radial probe endobronchial ultrasonography (radial EBUS) (1,2), offer more options for peripheral lung nodules diagnostic that are likely to be malignant (Figures 1,2). Moreover these tools combined with the recent possibility of bronchoscopic transparenchymatous biopsies open new diagnostic and therapeutic fields (3).

In the case of localized cancer, surgery remains the standard of care (4). When surgery is not possible, stereotactic radiotherapy (SBRT) is recommended (4). Percutaneous radiofrequency ablation (RFA) is an alternative treatment option (4,5). Stereotactic radiotherapy is expensive and includes radiation toxicities such as fibrosis, pneumonitis, cardiac toxicities and rib fractures. Percutaneous RFA has many adverse effects: pneumothoraces that may require chest tube insertion (22%) or even pleurodesis (1.6%), bleeding (1.6%), bronchopleural fistula (0.4%) and death (0.4%) (6).

The main advantage of ENB or radial EBUS over transparietal sampling is the low complication rate since no systematic puncture of the pleura is performed. Pneumothoraces occur in less than 10% (vs. more than 20% for CT-guided biopsies) and significant bleeding complications are very rare (vs. about 5% for transparietal sampling) (1,7). Also, endoscopic treatment of localized tumors seems an option to consider.

The endoscopic treatments of peripheral tumors without any node invasion raise some issues.

(I) The probe needs to be thin and flexible so that it can be inserted through a therapeutic endoscope;

(II) Good position of the therapeutic probe must be confirmed throughout the procedure by CT scan or fluoroscopy, eventually combined with EBUS;

(III) The area effect of the therapeutic probe needs to be known and should cover the whole tumor volume. In bulky tumors, multiple treatments can be necessary;

(IV) Physical conditions of the therapeutic probe must be known such as a high temperature for RFA;

(V) Since these treatments are emerging with incomplete safety information, they should preferably be performed close to a surgical unit.

Abstract: The expanded possibilities to explore the lung deeper with new tools such as electromagnetic navigation bronchoscopy (ENB) or radial probe endobronchial ultrasonography (radial EBUS), combined with miniaturization of traditional local therapies such as radiofrequency ablation (RFA), radiotherapy, cryotherapy or photodynamic therapy, let the bronchoscopists hope for new ways of endoscopic treatments. This challenge could change the practice in the upcoming decades but raise some physical and technical issues. Safety and efficacy need to be solidly established to face the serious concurrence of stereotactic radiotherapy (SBRT) or percutaneous RFA. Here we describe ongoing development and perspectives for endobronchial treatment of peripheral lung tumors.

Keywords: Lung neoplasm; bronchoscopy; local therapy

Submitted Jan 03, 2018. Accepted for publication Jan 10, 2018.
doi: 10.21037/jtd.2018.01.86

View this article at: http://dx.doi.org/10.21037/jtd.2018.01.86
After preclinical study on a sheep model (8), Tanabe et al. reported 10 cases of T1N0 lung cancer treated with various sizes and forms of RFA probes [5 mm, 8 mm (4 beads), 10 mm (5 beads)] (9). They used a cooled probe to prevent high temperature damages. Beads on the probe were used to enlarge the area of effect. The position of the probe was controlled by CT scan. They did not report any severe complication, only chest pain in 2 cases. The procedure was followed within 2 months by lung resection. With the largest probe, the tissue still contained few tumor cells at the border of the lesion. Histologic analysis indicated that the extent of the ablated area was 12 mm x 10 mm for the 10 mm probes. Then, 2 cases were published using the 10 mm (5 beads) probe in patients with a contraindication to surgery (10). No adverse effects were reported, and complete remission at 1 year was obtained in both cases. A third work from the same team was performed in 20 patients with clinical stage I cancers and a contraindication to surgery (11). They used their 10 mm cooled RFA probes on lung tumor (19–45 mm, without lymph nodes or metastasis involved). Control rate was 82% at 6 months (partial response 48%, stable disease 34%). Twelve lesions had to be retreated. Interestingly, 5-year overall survival was 61.5%. More recently, a team from Shanghai used ENB to guide RFA in 3 patients (12). No preclinical data were available. A bronchus sign, (defined by the visibility of a bronchus within the tumor on CT scan) was present for the 3 patients. Different probes were used with different area...
effect (15 to 30 mm). All 3 patients were in remission after 1 year. One patient has been retreated.

One prospective registry of ENB-guided RFA is currently active in clinicaltrials.gov (NCT03009630).

**Bronchoscopy to guide radiotherapy**

**Brachytherapy**

Brachytherapy is a highly localized radiation therapy. It has already been used for treatment of lung cancers of central airways (13). Only 2 studies have reported ENB-guided brachytherapy. It has been used to place a brachytherapy dedicated catheter in a few patients (14,15). Iridium 192 (15 to 30 Gy) was used in 10 patients and achieved complete remission. Nevertheless, compared to SBRT, this treatment seems to be less interesting for peripheral tumor. One prospective registry of ENB-guided brachytherapy is currently active in clinicaltrials.gov (NCT03051802).

**To help stereotactic radiosurgery**

Stereotactic radiotherapy may require fiducial markers to track respiration cycle and compensate for the changing tumor position (16), while reducing irradiation to the surrounding healthy lung. Fiducials can be inserted into intrathoracic tumors with different modalities: transthoracic, intravascular, and bronchoscopic (Figure 3). There are less pneumothoraces after bronchoscopy than after percutaneous placement (17). Nevertheless, there are alternative choices of tracking respiration which can reduce the indication for fiducial markers. The CYBERKNIFE® (Accuray, Sunnyvale, CA, USA) allows to not using fiducial with Xsight Spine Tracking System (18-20). Other machines may require using fiducial markers to reduce the radiotherapy field. The place to insert (within or around the tumor), and the number of fiducial markers (1 to 3 or more) to insert is not well established. The migration rate of some markers is very low (21).

**Cryotherapy**

Cryotherapy uses intense cold to destroy tissue. Through freeze–thaw cycles, cryotherapy causes cell death and tissue necrosis. It can be used with a rigid or flexible bronchoscope. Traditional method uses a nitrous oxide enclosed cryoprobe with a metal tip for heat transfer. Cryotherapy has shown efficacy in central tumors (22). Percutaneous approach has also been reported (23). Transbronchial cryobiopsy is an emerging technique for the diagnosis of parenchymal disease such as infiltrative...

**Photodynamische Therapie**


**Schlussfolgerungen**


**Anerkennungen**

Keine.

**Fußnote**

*Konflikte der Interessen:* Der thoraxische Abteilung erhielt Gebühren für Präsentation in einem Medtronic Symposium, die für unsere Organisation gestiftet wurden.

**Literatur**


